A content review of buprenorphine training programs for pharmacists

A content review of buprenorphine training programs for pharmacists

Objectives: To identify and describe continuing education (CE) credit-bearing training programs for pharmacists that cover buprenorphine dispensing. Methods: Five CE databases were searched for trainings that were in English, targeted to pharmacists, addressed use of buprenorphine for opioid use dis...

Full description

Bibliographic Details
Main Authors:	Scott A. Davis, Robyn Dryer, William Zule, Bayla Ostrach, Delesha M. Carpenter
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	Exploratory Research in Clinical and Social Pharmacy
Subjects:	Buprenorphine Training Opioid use disorder Communication Dispensing barriers
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667276622000531

Similar Items

Factors in rural community buprenorphine dispensing
by: Erin G. Major, et al.
Published: (2023-03-01)

Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia
by: Grace Trull, et al.
Published: (2021-12-01)

Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco
by: Jamie Carter, et al.
Published: (2019-05-01)

A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program
by: Amesika N. Nyaku, et al.
Published: (2024-02-01)

Patients' perspectives on buprenorphine subcutaneous implant: a case series
by: Claudio Pierlorenzi, et al.
Published: (2024-04-01)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
by: Ling W, et al.
Published: (2019-11-01)

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study
by: Zoe A. Karavolis, et al.
Published: (2022-12-01)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
by: Ling W, et al.
Published: (2020-01-01)

Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
by: Venumadhav Janganati, et al.
Published: (2023-05-01)

Buprenorphine Induction Using Microdosing for the Management of Opioid Use Disorder in Pregnancy
by: Neil B. Patel, et al.
Published: (2024-01-01)

Implementation of an education session on buprenorphine induction in the emergency department, a resident-led initiative
by: Cara Marie Borelli, et al.
Published: (2024-01-01)

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
by: Lindsay M. Mailloux, PharmD, et al.
Published: (2021-01-01)

Low-dose buprenorphine initiation during pregnancy: a case report
by: Shivania Reddy, BSc, et al.
Published: (2024-02-01)

Physicians’ satisfaction with providing buprenorphine treatment
by: Hannah K. Knudsen, et al.
Published: (2019-08-01)

Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
by: Benjamin L. H. Jones, et al.
Published: (2024-04-01)

Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
by: Erin L. Winstanley, et al.
Published: (2022-12-01)

Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018
by: Kevin P. Conway, et al.
Published: (2022-01-01)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
by: Megan K Reed, et al.
Published: (2022-12-01)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
by: Anita Silwal, et al.
Published: (2023-06-01)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
by: Lindsay McCormack, BA, et al.
Published: (2021-04-01)

Emergency department‐initiated buprenorphine protocols: A national evaluation
by: Clara Z. Guo, et al.
Published: (2021-12-01)

Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
by: Shane Kaski, et al.
Published: (2021-03-01)

Advancing emergency department–initiated buprenorphine
by: Kristen Huntley, et al.
Published: (2021-06-01)

Real-World Dispensing of Buprenorphine in California during Prepandemic and Pandemic Periods
by: Yun Wang, et al.
Published: (2024-01-01)

Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions
by: Cao SS, et al.
Published: (2020-10-01)

Single high-dose buprenorphine for opioid craving during withdrawal
by: Jamshid Ahmadi, et al.
Published: (2018-12-01)

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine
by: Ryu Komatsu, et al.
Published: (2022-06-01)

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data
by: William S. John, et al.
Published: (2022-06-01)

Transdermal buprenorphine for pain management in children
by: Giorgio Attinà, et al.
Published: (2021-09-01)

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort
by: Xi Wang, et al.
Published: (2023-12-01)

The introduction of a novel formulation of buprenorphine into organized health systems
by: William Mullen, et al.
Published: (2022-09-01)

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report
by: Scott Hagan, et al.
Published: (2021-12-01)

Emergency-department initiated buprenorphine: Impact on quality of life
by: Caleb Carroll, et al.
Published: (2023-12-01)

Epidural Naloxone to Prevent Buprenorphine Induced PONV
by: Ashok Jadon, et al.
Published: (2008-01-01)

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review
by: K. K. Adams, et al.
Published: (2021-06-01)

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series
by: Taylor A. Ochalek, et al.
Published: (2023-06-01)

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
by: Jarratt D. Pytell, et al.
Published: (2023-09-01)

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
by: Nikki Bozinoff, et al.
Published: (2022-10-01)

Commentary on physicians’ satisfaction with providing buprenorphine treatment by Knudsen et al.
by: Gavin Bart, et al.
Published: (2019-08-01)

The association of medical providers’ attitudes about naloxone and treating people with opioid use disorder and their self-reported low-barrier treatment practices
by: Rachel P. Winograd, et al.
Published: (2023-12-01)